Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamidronate versus alendronate for bone mineral density in thalassemia
IRCT2017070420258N51Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- Feb 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of pamidronate and alendronate in beta thalassemia major and beta-thalassemia intermedia (2 arms), sponsored by Arak University of Medical Sciences. Started Feb 2017; status: completed.
02
Drugs
pamidronatealendronate
03
Conditions
beta thalassemia majorbeta-thalassemia intermedia
Beyond the preview
Go deeper on IRCT2017070420258N51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017070420258N51.